TY - JOUR
T1 - Multifunctional yolk-shell nanoparticles
T2 - A potential MRI contrast and anticancer agent
AU - Gao, Jinhao
AU - Liang, Gaolin
AU - Cheung, Jerry S.
AU - Pan, Yue
AU - Kuang, Yi
AU - Zhao, Fan
AU - Zhang, Bei
AU - Zhang, Xixiang
AU - Wu, Ed X.
AU - Xu, Bing
PY - 2008/9/3
Y1 - 2008/9/3
N2 - We report a new type of multifunctional nanomaterials, FePt@Fe 2O3 yolk-shell nanoparticles, that exhibit high cytotoxicity originated from the FePt yolks and strong MR contrast enhancement resulting from the Fe2O3 shells. Encouraged by the recently observed high cytotoxicity of FePt@CoS2 yolk-shell nanoparticles, we used Fe2O3 to replace CoS2 as the shells to further explore the applications of the yolk-shell nanostructures. The ultralow IC50 value (238 ± 9 ng of Pt/mL) of FePt@Fe2O3 yolk-shell nanoparticles likely originates from the fact that the slow oxidation and release of FePt yolks increases the cytotoxicity. Moreover, compared with two commercial magnetic resonance imaging (MRI) contrast agents, MION and Sinerem, the FePt@Fe2O3 yolk-shell nanoparticle showed stronger contrast enhancement according to their apparent transverse relaxivity values (r2* = 3.462 (μg/mL)-1 s-1). The bifunctional FePt@Fe 2O3 yolk-shell nanoparticles may serve both as an MRI contrast agent and as a potent anticancer drug. This work indicates that these unique yolk-shell nanoparticles may ultimately lead to new designs of multifunctional nanostructures for nanomedicine.
AB - We report a new type of multifunctional nanomaterials, FePt@Fe 2O3 yolk-shell nanoparticles, that exhibit high cytotoxicity originated from the FePt yolks and strong MR contrast enhancement resulting from the Fe2O3 shells. Encouraged by the recently observed high cytotoxicity of FePt@CoS2 yolk-shell nanoparticles, we used Fe2O3 to replace CoS2 as the shells to further explore the applications of the yolk-shell nanostructures. The ultralow IC50 value (238 ± 9 ng of Pt/mL) of FePt@Fe2O3 yolk-shell nanoparticles likely originates from the fact that the slow oxidation and release of FePt yolks increases the cytotoxicity. Moreover, compared with two commercial magnetic resonance imaging (MRI) contrast agents, MION and Sinerem, the FePt@Fe2O3 yolk-shell nanoparticle showed stronger contrast enhancement according to their apparent transverse relaxivity values (r2* = 3.462 (μg/mL)-1 s-1). The bifunctional FePt@Fe 2O3 yolk-shell nanoparticles may serve both as an MRI contrast agent and as a potent anticancer drug. This work indicates that these unique yolk-shell nanoparticles may ultimately lead to new designs of multifunctional nanostructures for nanomedicine.
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000258792000052
UR - https://openalex.org/W2002916007
UR - https://www.scopus.com/pages/publications/51349102982
U2 - 10.1021/ja803920b
DO - 10.1021/ja803920b
M3 - Journal Article
C2 - 18681432
SN - 0002-7863
VL - 130
SP - 11828
EP - 11833
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 35
ER -
